Skip to content
Toggle main navigation
GMSLinked logo
GMSLinked logo
  • Events
  • Community
  • Events
  • Knowledge Hub
    Log in
    Request to join

    News

    Filter by category
    All
    Biotechnology
    Engineering
    Industrial IOT
    Maintenance, Reliability & Operations
    Manufacturing
    Pharmaceuticals
    Supply Chain

    Highlighted news

    Search results (52)

    New patent for Novartis drug VIJOICE

    New patent for Novartis drug VIJOICE

    Annual Drug Patent Expirations for VIJOICE Vijoice is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are two patents protecting…The post New patent for Novartis drug VIJOICE appeared first on DrugPatentWatch - Make Better Decisions.The post New patent for Novartis drug VIJOICE appeared first on Biotechblog.
    15 June 2023
    Silver-doped glass fibers used as a potential treatment for wound healing, finds study

    Silver-doped glass fibers used as a potential treatment for wound healing, finds study

    Researchers at the University of Birmingham have demonstrated that silver retains antimicrobial activity for longer when it is impregnated into 'bioactive glass', and shown for the first time how this promising combination delivers more long-lasting antimicrobial wound protection than conventional alternatives.
    15 June 2023
    Which pharmaceutical drugs have the most drug patents in Portugal?

    Which pharmaceutical drugs have the most drug patents in Portugal?

    This chart shows the drugs with the most patents in Portugal. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…The post Which pharmaceutical drugs have the most drug patents in Portugal? appeared first on DrugPatentWatch - Make Better Decisions.The post Which pharmaceutical drugs have the most drug patents in Portugal? appeared fi
    15 June 2023
    Acepodia raises $100M financing to boost cell therapies

    Acepodia raises $100M financing to boost cell therapies

    Acepodia, a clinical stage biotechnology company developing first-in-class cell therapies with its antibody-cell conjugation (ACC) and allogeneic gamma delta 2 T-cell platforms to address gaps in cancer care, has announced a $100 million Series D financing. The funds will be used to progress the company’s pipeline of enhanced cell therapies for solid tumors and hematologic […]The post Acepodia rai
    15 June 2023
    Kate Therapeutics launches with $51M to develop genetic medicines for muscle and heart diseases

    Kate Therapeutics launches with $51M to develop genetic medicines for muscle and heart diseases

    Gene therapy company Kate Therapeutics Inc. (KateTx), has emerged from stealth mode with a $51 million Series A financing. In addition, the company has granted Astellas Pharma Inc. an exclusive, worldwide license to develop, manufacture and commercialize KT430 to treat X-linked myotubular myopathy (XLMTM). There are a large number of genetically defined and complex muscle […]The post Kate Therapeu
    15 June 2023
    Anocca raises $36.6M for large-scale development of cancer cell therapies

    Anocca raises $36.6M for large-scale development of cancer cell therapies

    Anocca AB has raised SEK 400 million ($36.6 million) to further develop the discovery and manufacture of next generation cell therapies for cancer on an industrial scale. It will also allow Anocca to progress its first products into clinical trials. The financing brings together a group of existing and new investors, including Mellby Gård, AMF, […]The post Anocca raises $36.6M for large-scale deve
    15 June 2023
    ElevateBio raises $401M for cell and gene therapies

    ElevateBio raises $401M for cell and gene therapies

    ElevateBio, LLC (ElevateBio), a technology-driven company focused on cell and gene therapies, has closed its $401 million Series D financing. “We have made significant strides in scaling our technologies and end-to-end capabilities in our pursuit to become the world’s most indispensable cell and gene therapy technology company. We are thrilled to welcome Khalil to our […]The post ElevateBio raises
    15 June 2023
    Lonza boosts ADC portfolio with Synaffix acquisition

    Lonza boosts ADC portfolio with Synaffix acquisition

    Lonza has acquired Synaffix B.V., a biotech company focused on commercializing its clinical-stage technology platform for the development of antibody drug conjugates (ADCs).  While ADCs offer widespread and targeted treatment potential against cancer, they present a range of complex development and manufacturing challenges. Supported by a team of scientific experts, the Synaffix technology platfor
    15 June 2023
    Artificial intelligence combats lethal superbug, new antibody discovered

    Artificial intelligence combats lethal superbug, new antibody discovered

    A new antibiotic that can kill a deadly, drug-resistant pathogen has been discovered with the help of artificial intelligence (AI). Research published in Nature Chemical Biology showed that AI was able to rapidly screen 7,500 molecules that were found to inhibit the growth of the superbug Acinetobacter baumannii, a task that would be difficult to […]The post Artificial intelligence combats lethal
    15 June 2023
    New DNA testing technology shows majority of wild dingoes are pure, not hybrids

    New DNA testing technology shows majority of wild dingoes are pure, not hybrids

    Genetic analysis shows dingo populations have significantly less dog ancestry than previously thought.
    15 June 2023
    Convergent Therapeutics to use $90M funding to treat cancer with radiopharmaceuticals 

    Convergent Therapeutics to use $90M funding to treat cancer with radiopharmaceuticals 

    Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment of cancer, today announced the completion of a $90 million Series A financing. The funding was led by OrbiMed and RA Capital Management with participation from Invus. The financing will support the development of a pipeline of novel […]The post C
    12 May 2023
    The biggest private biotech investments in April 2023

    The biggest private biotech investments in April 2023

    April 2023 saw the companies Orbital Therapeutics, Sangon Biotech, and Alentis Therapeutics bag the biggest biotech investments of the month. Around the world, oncology, drug discovery, food and biomaterials attracted the biggest funding rounds. With reports of venture capital investments in biotech and pharma hitting a more than three-year low last quarter, private biotech fundraising […]The post
    12 May 2023
    Top 25 Biotech Companies of 2023

    Top 25 Biotech Companies of 2023

    Lost in all the talk about biotech stocks falling since the markets turned bearish two years ago is that overall, they have performed better than the market as a whole.Many biotech stocks sank deeper than the overall market during the first quarter, as GEN recently reported. But the first quarter (Q1) results were skewed by the banking crisis wrought by the collapses of Silicon Valley Bank and Sig
    12 May 2023
    MIT unlocks real-time powder particle size distribution monitoring

    MIT unlocks real-time powder particle size distribution monitoring

    Researchers have developed a physics-enhanced autocorrelation-based estimator (PEACE) machine learning algorithm that can extract the particle size distribution (PSD) of a pharmaceutical powder surface from its laser speckle. The method provides a real-time, non-invasive, far-field optical probe to monitor particle size distributions quantitatively. Estimating the appearance of large particles fro
    12 May 2023
    New patent expiration for Teva Branded drug PROAIR DIGIHALER

    New patent expiration for Teva Branded drug PROAIR DIGIHALER

    Annual Drug Patent Expirations for PROAIR+DIGIHALER Proair Digihaler is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from one supplier. There are…The post New patent expiration for Teva Branded drug PROAIR DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.The post New patent expiration for Teva Branded drug PROAIR DIGIHALER appeared first on B
    12 May 2023
    Whole Genome Sequencing for Cancer Arrives in the U.S. with Genome Insight

    Whole Genome Sequencing for Cancer Arrives in the U.S. with Genome Insight

    Up until now, genomics-based cancer detection tests have relied on gene panels. A whole genome sequencing (WGS) test has not been a viable option for multiple reasons, including the expense and the large amount (and complexity) of the data generated. However, given the falling cost of next generation sequencing (NGS), WGS may move into other areas where it has previously not been feasible. Young S
    12 May 2023
    Enzyme replacement therapy approved for Fabry disease

    Enzyme replacement therapy approved for Fabry disease

    A marketing authorisation for PRX-102 (pegunigalsidase alfa), the first Poly(ethylene glycol) (PEG)ylated enzyme for Fabry disease, has been granted by the European Commission (EC). The approval follows the European Medicines Agency (EMA) human medicines committee’s recommendation of the enzyme replacement therapy (ERT) in February 2023.CHMP recommends first pegylated enzyme for Fabry disease…The
    12 May 2023
    Which pharmaceutical companies have the most drug patents in Hong Kong?

    Which pharmaceutical companies have the most drug patents in Hong Kong?

    This chart shows the pharmaceutical companies with the most patents in Hong Kong. Patents must be filed in each country (or, in some cases regional patent office) where patent protection…The post Which pharmaceutical companies have the most drug patents in Hong Kong? appeared first on DrugPatentWatch - Make Better Decisions.The post Which pharmaceutical companies have the most drug patents in Hong
    12 May 2023
    New patent expiration for Sage Prods drug CHLORHEXIDINE GLUCONATE

    New patent expiration for Sage Prods drug CHLORHEXIDINE GLUCONATE

    Annual Drug Patent Expirations for CHLORHEXIDINE+GLUCONATE Chlorhexidine Gluconate is a drug marketed by Sage Prods, Akorn, Bajaj, Lyne, Pharm Assoc, Wockhardt Bio Ag, Xttrium, Becton Dickinson, and Kendall Il and,…The post New patent expiration for Sage Prods drug CHLORHEXIDINE GLUCONATE appeared first on DrugPatentWatch - Make Better Decisions.The post New patent expiration for Sage Prods drug C
    12 May 2023
    CRISPR genome-editing technology helps scientists to explore many cancer-linked mutations

    CRISPR genome-editing technology helps scientists to explore many cancer-linked mutations

    Genomic studies of cancer patients have revealed thousands of mutations linked to tumor development.
    12 May 2023
    Contact
    GMSLinked
    231-232 Strand Temple London WC2R 1DA United Kingdom
    info@gmstrats.com
    +44 (0) 207 952 6111
    Cookies
    Withdraw cookie consent
    Community engagement platform by Hivebrite.